On September 22, ASYMCHEM rose 3.01% in regular trading, trading at HK$164.5/share, with turnover of HK$68.84 million. The rebound came after a brief pullback driven by profit-taking following a sharp rally earlier in the month.
On the news front, ASYMCHEM disclosed on September 21 that its chemical macromolecule manufacturing base successfully completed a US FDA Pre-Approval Inspection (PAI) for an active pharmaceutical ingredient project. The four-day inspection, conducted from late June to early July, marked the first FDA inspection of this facility. FDA inspectors conducted a comprehensive review of quality systems, materials management, facility and equipment, production processes, and QC systems, with the production line maintaining normal operations throughout. The company received the FDA-issued Establishment Inspection Report (EIR) by late August, reaffirming its international regulatory compliance capabilities.
The positive regulatory milestone bolstered market confidence, complementing the company's solid fundamentals — first-half revenue of RMB 3.607 billion (up 13.13% YoY), orders-in-hand surging 54% YoY, and management guidance of 19%-22% full-year revenue growth.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments